Boehringer Ingelheim
boehringer-ingelheim.comTotal trials
2,275
Active
98
Phase 3
399
Total enrollment
15,710,354
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 106 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Spesolimab | — | 23 | |||||
| Empagliflozin | — | 56 | |||||
| Zongertinib | — | — | — | 13 | |||
| Carboplatin | — | — | — | 10 | |||
| Survodutide | — | — | — | 13 | |||
| Nerandomilast | — | — | — | — | 9 | ||
| Pembrolizumab | — | — | — | 7 | |||
| Vicadrostat | — | — | — | 6 | |||
| Etoposide | — | — | — | — | 4 | ||
| BI 1291583 | — | — | — | 15 | |||
| Cisplatin | — | — | — | 5 | |||
| Obrixtamig | — | — | — | — | 3 | ||
| Atezolizumab | — | — | — | — | 3 | ||
| BI 764198 | — | — | — | 11 | |||
| Pemetrexed | — | — | — | 9 | |||
| nivolumab | — | — | — | — | 2 | ||
| tenecteplase | — | — | — | — | 6 | ||
| Prednisone | — | — | — | 3 | |||
| BI 690517 | — | — | — | 9 | |||
| Nerandomilast formulation 1 | — | — | — | — | — | 1 | |
| Nerandomilast formulation 2 | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Standard of care treatment | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| BI 3000202 | — | — | — | — | 6 | ||
| BI 1584862 | — | — | — | — | 6 | ||
| BI 1015550 | — | — | — | 19 | |||
| Brigimadlin | — | — | — | — | 5 | ||
| trastuzumab | — | — | — | 5 | |||
| BI 1815368 | — | — | — | — | 5 | ||
| BI 765423 | — | — | — | — | 3 | ||
| BI 3802876 | — | — | — | — | 2 | ||
| BI 3720931 | — | — | — | — | — | 2 | |
| Capecitabine | — | — | — | — | — | 2 | |
| BI 764524 | — | — | — | — | — | 2 | |
| BI 771716 | — | — | — | — | 2 | ||
| Trastuzumab deruxtecan | — | — | — | — | — | 1 | |
| Trastuzumab emtansine | — | — | — | — | — | 1 | |
| mFOLFOX6 | — | — | — | — | — | 1 | |
| zanidatamab | — | — | — | — | — | 1 |
66 more active programs hidden
Next readouts
- 2024-07-15
- 2024-07-16
- 2025-06-11
- 2026-01-14
- 2026-04-27
- 2026-05-08
- 2026-05-11
- 2026-05-18
- 2026-05-23
- 2026-05-28
Top conditions
- Healthy798
- Pulmonary Disease, Chronic Obstructive232
- Diabetes Mellitus, Type 2126
- Hypertension122
- HIV Infections67
- Asthma62
- Neoplasms57
- Carcinoma, Non-Small-Cell Lung56
Frequently asked questions about Boehringer Ingelheim
- How many clinical trials does Boehringer Ingelheim have on ClinicalTrials.gov?
- Boehringer Ingelheim is listed as the lead sponsor on 2,275 clinical trials in ClinicalTrials.gov, 98 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Boehringer Ingelheim's trials are in Phase 3?
- 399 of Boehringer Ingelheim's trials are in Phase 3, spread across 106 active drug programs.
- What therapeutic areas does Boehringer Ingelheim focus on?
- Boehringer Ingelheim's most-studied conditions on ClinicalTrials.gov are Healthy, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Type 2, Hypertension, HIV Infections.
- When are Boehringer Ingelheim's next clinical trial readouts?
- Boehringer Ingelheim has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer”, expected around 2024-07-15.